Bipolar Disorder

IN: the clinical ecosystem of bipolar disorder - genetic and neurobiological drivers, behavioural and environmental triggers, episode phases, diagnosis, pharmacotherapy and psychotherapy, comorbidities, patient outcomes, and the drugmakers behind core treatments. OUT: unrelated psychiatric conditions, general wellness lifestyle content, individual celebrity-diagnosis stories, and non-clinical stigma commentary.

This causal map links 51 factors across 56 relationships. The strongest:

• Medication Adherence decreases Relapse Rate. Confidence: 56%.
• Antipsychotic Treatment decreases Depressive Episode. Confidence: 41%.
• Antipsychotic Treatment decreases Manic Episode. Confidence: 39%.
• Sleep Deprivation triggers Manic Episode. Confidence: 38%.
• Abbvie enables Antipsychotic Treatment. Confidence: 36%.
• Psychoeducation decreases Relapse Rate. Confidence: 32%.
• Thyroid Hormone Mimic enables Autobahn Therapeutics Pivotal Trial. Confidence: 32%.
• Misdiagnosis enables Antidepressant Induced Mania. Confidence: 31%.
• Electroconvulsive Therapy decreases Depressive Episode. Confidence: 31%.
• Magnetic Seizure Therapy decreases Depressive Episode. Confidence: 31%.
• Magnetic Seizure Therapy increases Treatment Safety. Confidence: 30%.
• Thyroid Hormone Mimic decreases Depressive Episode. Confidence: 30%.
• Substance Use increases Psychosis Risk. Confidence: 29%.
• Psychosis Risk increases Schizophrenia Risk. Confidence: 28%.
• Negativity Bias enables Depressive Episode. Confidence: 27%.
• Excessive Sleep decreases Cognitive Performance. Confidence: 27%.
• Family History Of Mood Disorder increases Genetic Predisposition. Confidence: 27%.
• Genetic Predisposition enables Anxiety Comorbidity. Confidence: 27%.
• Personality Traits correlates with Depressive Episode. Confidence: 27%.
• Substance Use increases Dopamine Dysregulation. Confidence: 27%.
• Intra Cellular Therapies enables Antipsychotic Treatment. Confidence: 27%.
• Personality Traits correlates with Functional Impairment. Confidence: 26%.
• Sgk1 Overexpression increases Suicide Risk. Confidence: 26%.
• Genetic Predisposition enables Substance Use. Confidence: 25%.
• Sgk1 Inhibitor Treatment decreases Depressive Episode. Confidence: 25%.
• Bipolar Disorder decreases Brain Network Efficiency. Confidence: 25%.
• Neuroinflammation increases Depressive Episode. Confidence: 25%.
• Neuroinflammation increases Manic Episode. Confidence: 25%.
• Personality Assessment enables Bipolar Disorder Treatment Precision. Confidence: 25%.
• Skin Condition Comorbidity increases Suicide Risk. Confidence: 23%.
• Fitness Tracker Data enables Manic Episode. Confidence: 22%.
• Sunlight Exposure correlates with Physical Activity. Confidence: 22%.
• Bipolar Disorder Severity correlates with Brain Network Changes. Confidence: 21%.
• Genetic Predisposition increases Manic Episode. Confidence: 21%.
• Multimodal Eeg Fnirs Classification prevents Misdiagnosis. Confidence: 21%.
• Genetic Predisposition enables Manic Episode. Confidence: 19%.
• Lithium Treatment decreases Relapse Rate. Confidence: 19%.
• Paraventricular Thalamic Nucleus Disturbance correlates with Manic Episode. Confidence: 19%.
• Substance Use increases Suicide Risk. Confidence: 19%.
• Manic Episode triggers Misdiagnosis. Confidence: 18%.
• Psychotic Like Experiences correlates with Depressive Episode. Confidence: 17%.
• Anxiety Comorbidity increases Misdiagnosis. Confidence: 15%.
• Early Episode Onset increases Relapse Rate. Confidence: 15%.
• Misdiagnosis increases Relapse Rate. Confidence: 15%.